Dr. Michelle T. Long, MD, MSc is a physician scientist, hepatologist, and epidemiologist with an expertise in MASLD/MASH and the intersection between the liver and cardiometabolic disease. She has led numerous studies within the Framingham Heart Study evaluating the association between liver fat and fibrosis and cardiometabolic disease. Dr. Long is an Associate Professor of Medicine at Boston University School of Medicine. In July of 2022 she joined Novo Nordisk as the International Medical Vice President for MASH and Liver Diseases. At Novo Nordisk Dr. Long provides strategic insights and guidance to the clinical development portfolios, leads several external partnerships, and provides strategic and scientific guidance to the MASH portfolio.